3-哌啶-1-丙酸肼 | 29800-31-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3-哌啶-1-丙酸肼
• 中文别名: 3-哌啶-1-基丙酰肼；3-(1-哌啶基)丙烷肼；3-哌啶-1-基丙烷肼；3-哌啶-1-基-丙酸,肼
• 英文名称: 3-Piperidino-propionohydrazid
• 英文别名: 3-Piperidinopropionsaeurehydrazid；3-(piperidin-1-yl)propanehydrazide；3-piperidin-1-ylpropanehydrazide
• CAS: 29800-31-5
• 化学式: C₈H₁₇N₃O
• mdl: MFCD01162522
• 分子量: 171.242
• InChiKey: AWVBNMXEAMVLLQ-UHFFFAOYSA-N

物化性质

• 沸点：
  122 °C(Press: 0.1 Torr)
• 密度：
  1.062±0.06 g/cm3(Predicted)
• 溶解度：
  17.2 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  58.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  3-哌啶-1-丙酸肼 在 盐酸 、 sodium nitrate 作用下， 以 水 为溶剂， 反应 7.0h， 以81%的产率得到1-(2-氨乙基)哌啶
  参考文献：
  名称：

  Yao, Ri-Sheng; Jiang, Lai-En; Wu, Sheng-Hua, Asian Journal of Chemistry, 2011, vol. 23, # 9, p. 3792 - 3794

  摘要：

  DOI：
• 作为产物：
  描述：

  3-(1-哌啶基)-丙酸乙酯 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 5.5h， 以95%的产率得到3-哌啶-1-丙酸肼
  参考文献：
  名称：

  Yao, Ri-Sheng; Jiang, Lai-En; Wu, Sheng-Hua, Asian Journal of Chemistry, 2011, vol. 23, # 9, p. 3792 - 3794

  摘要：

  DOI：

文献信息

• ESTROGEN MODULATORS
  申请人：Bailey Simon

  公开号：US20070149564A1

  公开（公告）日：2007-06-28

  The present application is directed to a new class of isoxazoles and their use as estrogen modulators.

  本申请涉及一种新型异噁唑类化合物及其作为雌激素调节剂的用途。
• AROMATIC AMIDE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME, MEDICAL USES OF BOTH
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1813603A1

  公开（公告）日：2007-08-01

  A present invention provides aromatic amide derivatives which have an agonism of V2 receptor, are useful as agents for the treatment or prevention of diabetes insipidus, nocturia, nocturnal enuresis, overactive bladder or the like, and are represented by the general formula (I): wherein R1 represents a hydrogen atom or a C1-6 alkyl group which may have a substituent, R2 is a hydrogen atom or a C1-6 alkyl group, R3 is a hydrogen atom, a C1-6 alkyl group or the like, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, R7 is a hydrogen atom, a heteroaryl group which may have a substituent, a C3-8 cycloalkyl group', an amino group which may have a substituent or a C1-6 alkoxy group which may have a substituted group; M1 is a single bond, a C1-4 alkylene group or the like Y is N or CRF (in the formula, RF represents a hydrogen atom, a C1-6 alkyl group or the like or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or pharmaceutical compositions comprising the same and pharmaceutical uses thereof.

  本发明提供了具有V2受体激动作用的芳香酰胺衍生物，可用作治疗或预防尿崩症、夜尿症、夜间遗尿、膀胱过度活跃或类似疾病的药物，并由通式（I）表示： 其中R1代表氢原子或可能具有取代基的C1-6烷基基团，R2是氢原子或C1-6烷基基团，R3是氢原子、C1-6烷基基团或类似物，R4、R5和R6独立地是氢原子、卤原子或类似物，R7是氢原子、可能具有取代基的杂环基团、C3-8环烷基团、可能具有取代基的氨基团或可能具有取代基的C1-6烷氧基团；M1是单键、C1-4烷基烃基团或类似物，Y是N或CRF（在该式中，RF代表氢原子、C1-6烷基基团或类似物），或其药学上可接受的盐，或其前药，或包含其的药物组合物和药物用途。
• Aromatic amide derivatives, medicinal compositions containing the same, medical uses of both
  申请人：Yokoyama Kenji

  公开号：US20070232594A1

  公开（公告）日：2007-10-04

  A present invention provides aromatic amide derivatives which have an agonism of V2 receptor, are useful as agents for the treatment or prevention of diabetes insipidus, nocturia, nocturnal enuresis, overactive bladder or the like, and are represented by the general formula (I): wherein R 1 represents a hydrogen atom or a C 1-6 alkyl group which may have a substituent, R 2 is a hydrogen atom or a C 1-6 alkyl group, R 3 is a hydrogen atom, a C 1-6 alkyl group or the like, R 4 , R 5 and R 6 are independently a hydrogen atom, a halogen atom or the like, R 7 is a hydrogen atom, a heteroaryl group which may have a substituent, a C 3-8 cycloalkyl group, an amino group which may have a substituent or a C 1-6 alkoxy group which may have a substituted group; M 1 is a single bond, a C 1-4 alkylene group or the like Y is N or CR F (in the formula, R F represents a hydrogen atom, a C 1-6 alkyl group or the like or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or pharmaceutical compositions comprising the same and pharmaceutical uses thereof.

  本发明提供了具有V2受体激动作用的芳香酰胺衍生物，可用作治疗或预防尿崩症、夜尿症、夜间遗尿、过度活动膀胱等药物，其通式表示为（I）：其中R1表示氢原子或C1-6烷基，可以有取代基，R2表示氢原子或C1-6烷基，R3表示氢原子、C1-6烷基或类似物，R4、R5和R6分别表示氢原子、卤原子或类似物，R7表示氢原子、可以有取代基的杂环芳基、C3-8环烷基、可以有取代基的氨基或C1-6烷氧基；M1表示单键、C1-4烷基等，Y表示N或CRF（在公式中，RF表示氢原子、C1-6烷基或类似物的药物可接受的盐，或其前药，或包含它的制药组合物和制药用途）。
• POLYACETAL RESIN COMPOSITION
  申请人：Polyplastics Co., Ltd.

  公开号：EP1686156A1

  公开（公告）日：2006-08-02

  A polyacetal resin composition comprises a polyacetal resin and a hetero atom-containing aliphatic carboxylic acid hydrazide. The proportion of the hetero atom-containing aliphatic carboxylic acid hydrazide may be about 0.001 to 20 parts by weight relative to 100 parts by weight of the polyacetal resin. The polyacetal resin composition may further comprise at least one member selected from the group consisting of an antioxidant, a heat stabilizer, a processing stabilizer, a weather (light)-resistant stabilizer, an impact resistance improver, a gloss control agent, an agent for improving sliding property, a coloring agent, and a filler. Such a resin composition improves stability of the polyacetal resin and inhibits formaldehyde emission.

  聚缩醛树脂组合物由聚缩醛树脂和含杂原子的脂肪族羧酸酰肼组成。相对于 100 重量份的聚缩醛树脂，含杂原子的脂肪族羧酸酰肼的比例可为 0.001 至 20 重量份。聚缩醛树脂组合物可进一步包含至少一种选自以下组别的成员：抗氧化剂、热稳定剂、加工稳定剂、耐候（光）稳定剂、抗冲击性改进剂、光泽控制剂、改善滑动性能剂、着色剂和填料。这种树脂组合物可以提高聚缩醛树脂的稳定性，并抑制甲醛释放。
• Development of Nonpeptidic Inverse Agonists of the Ghrelin Receptor (GHSR) Based on the 1,2,4-Triazole Scaffold
  作者：Khoubaib Ben Haj Salah、Mathieu Maingot、Anne-Laure Blayo、Céline M’Kadmi、Marjorie Damian、Sophie Mary、Sonia Cantel、Jérémie Neasta、Catherine Oiry、Sylvie Péraldi-Roux、Gimena Fernandez、Guadalupe García Romero、Mario Perello、Jacky Marie、Jean-Louis Banères、Jean-Alain Fehrentz、Séverine Denoyelle

  DOI：10.1021/acs.jmedchem.9b02122

  日期：2020.10.8

  GHSR controls, among others, growth hormone and insulin secretion, adiposity, feeding, and glucose metabolism. Therefore, an inverse agonist ligand capable of selectively targeting GHSR and reducing its high constitutive activity appears to be a good candidate for the treatment of obesity-related metabolic diseases. In this context, we present a study that led to the development of several highly potent and selective inverse agonists of GHSR based on the 1,2,4-triazole scaffold. We demonstrate that, depending on the nature of the substituents on positions 3, 4, and 5, this scaffold leads to ligands that exert an intrinsic inverse agonist activity on GHSR-catalyzed G protein activation through the stabilization of a specific inactive receptor conformation. Thanks to an in vivo evaluation, we also show that one of the most promising ligands not only exerts an effect on insulin secretion in rat pancreatic islets but also affects the orexigenic effects of ghrelin in mice.